Tickernomics

10y

Historical Returns*:

SPY

27.80%

-50.18%

ALBT

SPY

32.66%

-97.34%

ALBT

SPY

108.59%

-98.80%

ALBT

SPY

302.52%

ALBT

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

3.30

11.03

0.04

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-0.22

2.52

0.61

-162.52

0.00

-2.41

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-367.94

28.87

-344.22

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

-1291.0032

-30.24

-32.59

-351.99

Other Earnings and Cash Flow Stats:

Avalon GloboCare Corp. ( ALBT ) Net Income TTM ($MM) is -14.73

Avalon GloboCare Corp. ( ALBT ) Operating Income TTM ($MM) is -4.47

Avalon GloboCare Corp. ( ALBT ) Owners' Earnings Annual ($MM) is -7.47

Avalon GloboCare Corp. ( ALBT ) Current Price to Owners' Earnings ratio is -10.60

Avalon GloboCare Corp. ( ALBT ) EBITDA TTM ($MM) is -4.17

Avalon GloboCare Corp. ( ALBT ) EBITDA Margin is -344.22%

Capital Allocation:

Avalon GloboCare Corp. ( ALBT ) has paid 0.00 dividends per share and bought back 9.871058 million shares in the past 12 months

Avalon GloboCare Corp. ( ALBT ) has increased its debt by 0.406155 million USD in the last 12 months

Capital Structure:

Avalon GloboCare Corp. ( ALBT ) Interest-bearing Debt ($MM) as of last quarter is 8

Avalon GloboCare Corp. ( ALBT ) Annual Working Capital Investments ($MM) are 1

Avalon GloboCare Corp. ( ALBT ) Book Value ($MM) as of last quarter is 5

Avalon GloboCare Corp. ( ALBT ) Debt/Capital as of last quarter is 162%

Other Balance Sheet Stats:

Avalon GloboCare Corp. ( ALBT ) has 1 million in cash on hand as of last quarter

Avalon GloboCare Corp. ( ALBT ) has 12 million of liabilities due within 12 months, and long term debt 8 as of last quarter

Avalon GloboCare Corp. ( ALBT ) has 0 common shares outstanding as of last quarter

Avalon GloboCare Corp. ( ALBT ) has 0 million USD of preferred stock value

Academic Scores:

Avalon GloboCare Corp. ( ALBT ) Altman Z-Score is -7.37 as of last quarter

Avalon GloboCare Corp. ( ALBT ) Piotroski Score is 4.00 as of last quarter

Corporate Governance:

Avalon GloboCare Corp. ( ALBT ) largest shareholder is HRT FINANCIAL LP owning 27058 shares at 0.10 ($MM) value

(an insider) shares of Avalon GloboCare Corp. ( ALBT ) for the amount of $ on

37.47% of Avalon GloboCare Corp. ( ALBT ) is held by insiders, and 1.53% is held by institutions

Avalon GloboCare Corp. ( ALBT ) went public on 2016-12-06

About Avalon GloboCare Corp. ( ALBT ) :

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.